<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517864</url>
  </required_header>
  <id_info>
    <org_study_id>B7981037</org_study_id>
    <secondary_id>2020-001509-21</secondary_id>
    <nct_id>NCT04517864</nct_id>
  </id_info>
  <brief_title>PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA</brief_title>
  <acronym>Allegro2a</acronym>
  <official_title>A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the&#xD;
      safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp&#xD;
      hair loss due to Alopecia Areata (AA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">May 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in I-V interwave latency on brainstem auditory evoked potential (BAEP) at a stimulus intensity of 80 decibels (dB) at Month 9.</measure>
    <time_frame>Baseline, Month 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in I-V interwave latency on BAEP at a stimulus intensity of 80dB at Months 6, 18 (aka 9E), and 24 (15E)</measure>
    <time_frame>Baseline, Months 6, 18(month 9 of active therapy extension [9E]), 24 (15E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in axonal dystrophy in skin punch biopsies at Month 9 and Month 24 (15E)</measure>
    <time_frame>Baseline, Months 9, 24 (15E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IENFD in skin punch biopsies at Month 9 and Month 24 (15E)</measure>
    <time_frame>Baseline, Months 9, 24 (15E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in amplitude of wave V on BAEP at a stimulus intensity of 80 dB at Months 6, 9, 18 (9E), and 24 (15E)</measure>
    <time_frame>Baseline, Months 6, 9, 18 (9E), 24 (15E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB at Months 6, 9, 18 (9E) and 24 (15E)</measure>
    <time_frame>Baseline, Months 6, 9, 18 (9E), 24 (15E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), and adverse events (AEs) leading to discontinuation</measure>
    <time_frame>Baseline through Month 24 (15E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in vital signs</measure>
    <time_frame>Baseline through Month 24 (15E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in clinical laboratory values</measure>
    <time_frame>Baseline through Month 24 (15E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate response to ritlecitinib measured by the Severity of Alopecia Tool (SALT) in adult participants with AA</measure>
    <time_frame>Baseline through Month 24 (15E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the response to ritlecitinib measured by the Patient's Global Impression of Change (PGI-C) tool in adult participants with AA</measure>
    <time_frame>Baseline through Month 24 (15E)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Treatment Arm: PF-06651600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ritlecitinib 200 milligram (mg) once per day (QD) (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. At Month 9, participants assigned to this treatment arm will also receive 3 tablets of placebo for 4 weeks to maintain the blind with the other arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm (Placebo) followed by active therapy extension</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>matching comparator: placebo QD (4 tablets x 4 weeks then 1 tablet x 8 months) then ritlecitinib 200 mg QD (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06651600</intervention_name>
    <description>50 mg tablet, dosed as 200 mg QD or 50 mg QD</description>
    <arm_group_label>Treatment Arm: PF-06651600</arm_group_label>
    <other_name>ritlecitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, dosed as 4 tablets QD or 1 tablet QD</description>
    <arm_group_label>Control Arm (Placebo) followed by active therapy extension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of alopecia areata, including alopecia totalis and alopecia universalis.&#xD;
&#xD;
          -  At least 25% hair loss due to alopecia areata&#xD;
&#xD;
          -  Must have normal hearing and normal brainstem auditory evoked potentials (BAEPs)&#xD;
&#xD;
          -  Must have a normal neurological exam; can have a stable unilateral median neuropathy&#xD;
             or ulnar neuropathy&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Stable regimen for other medications before and during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other significant medical conditions&#xD;
&#xD;
          -  Occupational or recreational noise exposure&#xD;
&#xD;
          -  History of peripheral neuropathy or first degree relative with a hereditary peripheral&#xD;
             neuropathy&#xD;
&#xD;
          -  HbA1c &gt; or = 7.5% at Screening&#xD;
&#xD;
          -  Recurrent or disseminated Herpes Zoster&#xD;
&#xD;
          -  Active or chronic infection; or infection requiring hospitalization or IV&#xD;
             antimicrobials within 6 months&#xD;
&#xD;
          -  Active or latent (insufficiently treated) Hepatitis&#xD;
&#xD;
          -  Active or latent (insufficiently treated) TB&#xD;
&#xD;
          -  Concomitant medications associated with peripheral neurologic or hearing loss&#xD;
&#xD;
          -  Protocol specific laboratory abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marvel Clinical Research 002, LLC</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care Research, LLC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care Research, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kendall Adkisson, MD - Intracoastal Dermatology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Y&amp;L Advance Health Care Inc., d/b/a Elite Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center Inc</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc. dba CNS Healthcare</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Dermatology &amp; Skin Cancer Surgery Center</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center Inc.</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF Health Morsani Center For Advanced Healthcare</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem Dermatology Clinical Trials Unit</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem Dermatology Clinic</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine-Dermatology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Department of Dermatology</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Clinical &amp; Translational Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Dermatology</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research, Inc</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies, LTD. LLP</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research, LLC</name>
      <address>
        <city>Franklin</city>
        <state>Virginia</state>
        <zip>23851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education &amp; Research Foundation, Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Dermatology and Skin Cancer Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Specialists Pty Ltd</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Health - Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKiN Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sima Recherche</name>
      <address>
        <city>Verdun</city>
        <state>Quebec</state>
        <zip>H4G 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Saint-Louis</name>
      <address>
        <city>Quebec</city>
        <zip>G1W4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Specjalistyczny Osrodek Dermatologiczny &quot;DERMAL&quot;</name>
      <address>
        <city>Bialystok</city>
        <zip>15-453</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Angelius Provita</name>
      <address>
        <city>Katowice</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AWP Klinika Dermatologii Pod Fortem Anna Wojas-Pelc</name>
      <address>
        <city>Krakow</city>
        <zip>31-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermedic Jacek Zdybski</name>
      <address>
        <city>Ostrowiec Swietokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCMed Oddzial Warszawa</name>
      <address>
        <city>Warszawa</city>
        <zip>00-892</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research Sp. z o.o</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przychodnia przy ul. Lowieckiej</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Matusiak</name>
      <address>
        <city>Wrocław</city>
        <zip>50-566</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7981037</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alopecia totalis</keyword>
  <keyword>alopecia universalis</keyword>
  <keyword>hair loss</keyword>
  <keyword>alopecia</keyword>
  <keyword>JAK</keyword>
  <keyword>ritlecitinib</keyword>
  <keyword>PF-06651600</keyword>
  <keyword>double-blind</keyword>
  <keyword>placebo-controlled</keyword>
  <keyword>phase 2a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

